These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 7812918

  • 1. Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent.
    Higuchi T, Okada S, Mori H, Niikura H, Omine M, Terada H.
    Cancer; 1995 Jan 15; 75(2):471-7. PubMed ID: 7812918
    [Abstract] [Full Text] [Related]

  • 2. Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.
    Passamonti F, Lazzarino M.
    Leuk Lymphoma; 2003 Sep 15; 44(9):1483-8. PubMed ID: 14565648
    [Abstract] [Full Text] [Related]

  • 3. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
    Alvarez-Larrán A, Martínez-Avilés L, Hernández-Boluda JC, Ferrer-Marín F, Antelo ML, Burgaleta C, Mata MI, Xicoy B, Martínez-Trillos A, Gómez-Casares MT, Durán MA, Marcote B, Ancochea A, Senín A, Angona A, Gómez M, Vicente V, Cervantes F, Bellosillo B, Besses C.
    Ann Hematol; 2014 Dec 15; 93(12):2037-43. PubMed ID: 24981691
    [Abstract] [Full Text] [Related]

  • 4. Acute leukemia following treatment of polycythemia vera and essential thrombocythemia with uracil mustard.
    Toh BT, Gregory SA, Knospe WH.
    Am J Hematol; 1988 May 15; 28(1):58-60. PubMed ID: 3369437
    [Abstract] [Full Text] [Related]

  • 5. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
    Lim Y, Lee JO, Kim SH, Kim JW, Kim YJ, Lee KW, Lee JS, Bang SM.
    Thromb Res; 2015 May 15; 135(5):846-51. PubMed ID: 25743883
    [Abstract] [Full Text] [Related]

  • 6. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
    Barbui T, Finazzi G.
    Semin Thromb Hemost; 2007 Jun 15; 33(4):321-9. PubMed ID: 17525889
    [Abstract] [Full Text] [Related]

  • 7. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S, Stock W, Godwin J, Fisher SG.
    Am J Hematol; 1996 May 15; 52(1):42-6. PubMed ID: 8638610
    [Abstract] [Full Text] [Related]

  • 8. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
    Lussana F, Rambaldi A, Finazzi MC, van Biezen A, Scholten M, Oldani E, Carobbio A, Iacobelli S, Finke J, Nagler A, Volin L, Lamy T, Arnold R, Mohty M, Michallet M, de Witte T, Olavarria E, Kröger N.
    Haematologica; 2014 May 15; 99(5):916-21. PubMed ID: 24389309
    [Abstract] [Full Text] [Related]

  • 9. Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group.
    Dan K, Yamada T, Kimura Y, Usui N, Okamoto S, Sugihara T, Takai K, Masuda M, Mori M, Japanese Elderly Leukemia and Lymphoma Study Group.
    Int J Hematol; 2006 Jun 15; 83(5):443-9. PubMed ID: 16787877
    [Abstract] [Full Text] [Related]

  • 10. Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia.
    Randi ML, Fabris F, Ruzzon E, Pacquola E, Cella G, Girolami A.
    Haematologica; 2002 Nov 15; 87(11):1180-4. PubMed ID: 12414348
    [Abstract] [Full Text] [Related]

  • 11. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
    Finazzi G, Barbui T.
    Blood Rev; 2005 Sep 15; 19(5):243-52. PubMed ID: 15963833
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.
    Choi HS, Hong J, Hwang SM, Lee JH, Ma Y, Kim SA, Lee JY, Lee JO, Bang SM.
    Ann Hematol; 2021 Oct 15; 100(10):2567-2574. PubMed ID: 34331110
    [Abstract] [Full Text] [Related]

  • 13. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B, Rattarittamrong E, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Tantiworawit A, Norasetthada L.
    Asian Pac J Cancer Prev; 2015 Oct 15; 16(12):5013-8. PubMed ID: 26163633
    [Abstract] [Full Text] [Related]

  • 14. Acute coronary disease in essential thrombocythemia and polycythemia vera.
    Rossi C, Randi ML, Zerbinati P, Rinaldi V, Girolami A.
    J Intern Med; 1998 Jul 15; 244(1):49-53. PubMed ID: 9698024
    [Abstract] [Full Text] [Related]

  • 15. Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients.
    Mavrogianni D, Viniou N, Michali E, Terpos E, Meletis J, Vaiopoulos G, Madzourani M, Pangalis G, Yataganas X, Loukopoulos D.
    Int J Hematol; 2002 May 15; 75(4):394-400. PubMed ID: 12041671
    [Abstract] [Full Text] [Related]

  • 16. Essential thrombocythemia and leukemic transformation.
    Sedlacek SM, Curtis JL, Weintraub J, Levin J.
    Medicine (Baltimore); 1986 Nov 15; 65(6):353-64. PubMed ID: 3465986
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera.
    Rottenstreich A, Kleinstern G, Krichevsky S, Varon D, Lavie D, Kalish Y.
    Eur J Intern Med; 2017 Jun 15; 41():49-54. PubMed ID: 27919526
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.